Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HaploX Biotechnology

Request full access

Shenzhen-based genetic sequencing company

Shenzhen, ChinaFounded 2014Biotech & Life Sciences

About HaploX Biotechnology

Founded in 2014 by Mingyan Xu, Wen Yuan, Fang Wen, and Chen Shi Fu, HaploX Biotechnology is a Shenzhen-based enterprise focused on genomic and precision medicine. Mingyan Xu, who serves as the Chairman and CEO, leads the company. The company has established itself in the field of ultra-micro tumor gene detection, leveraging genomics technology for cancer diagnosis. HaploX has secured significant funding across multiple rounds, including a Series A in 2016, a $32 million Series A+ in 2018, and subsequent Series B, C, and D rounds, with its latest funding round being a Series D in July 2022.

HaploX operates in the biotechnology and diagnostic equipment industries, specializing in liquid biopsy, gene sequencing, bioinformatics, and big data analytics. The company's business model centers on providing comprehensive genetic testing solutions and services. Its clients include Class IIIA hospitals, biopharmaceutical companies, research institutes, health examination centers, insurance companies, and government bodies across China. Revenue is generated through these services, which cover the full cycle of cancer management, from early screening and diagnosis to health management and risk assessment. The company has also formed a strategic partnership with Illumina, a global leader in DNA sequencing, to domestically produce a genetic sequencing system, signaling a strategic shift from a service provider to a developer of clinical application products.

The company's core offering involves advanced technology for capturing circulating tumor DNA (ctDNA) and extracting and amplifying minute amounts of DNA from liquid samples. Its product and service portfolio is extensive, including pan-solid tumor gene testing, minimal residual disease (MRD) gene testing, and hereditary cancer gene testing under brand names like HapOnco®. Additionally, HaploX provides multi-omics technology services for research, covering human, plant, animal, and microbial genomics, transcriptomics, and single-cell sequencing. For the biopharmaceutical sector, it offers central laboratory services, patient recruitment, and exploratory research services. The company's laboratories have received accreditations from the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA).

Source: Dealroom company data

At a glance

Status
Operational
Employees
20
Open positions
None listed
Dealroom signal
69.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Jul 2022 $28M $110M SB China Capital · Tongrentang Pension Investment · CNCB Capital · Tongrentang ↗
SERIES BOther financing Jun 2018 $30M $121M Shenzhen Capital Group —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

HaploX Biotechnology website traffic

Latest recorded traffic for HaploX Biotechnology is 1.3K monthly website visits, down 7.1% over the last three months. HaploX Biotechnology's team declined 4.8% over the past year.

Latest monthly visits1.3K 3-month web change-7.1% 1-year team growth-4.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Immitra BioAt Ariya Bio we focus on hereditary blood diseases and employ cutting-edge genome engineering tools to develop next-generation cell and gene therapies Schlieren, Switzerland Operational 5 $2.4M $8.8M
Affini-T TherapeuticsBiotechnology company developing T-cell therapies for patients suffering from cancer Boston, United States Operational
Ray TherapeuticsDeveloping optogenetic gene therapies to restore vision in patients with blinding diseases Berkeley, United States Operational
Scribe TherapeuticsFocused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders Alameda, United States Operational
Graphite BioA next-generation gene editing company focused on fixing genes through targeted DNA integration to cure serious diseases San Francisco, United States Acquired
Modalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders Cambridge, United States Operational
Verve TherapeuticsFocused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary Cambridge, United States Acquired
GenEditDeveloping innovative therapies through targeted delivery of genetic medicines Brisbane, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

HaploX Biotechnology in the Shenzhen ecosystem

Live from Dealroom

The HaploX Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Series B and later4 investors entered at this stage

  • SB China Capital
  • Tongrentang Pension Investment
  • CNCB Capital
  • Tongrentang

Other known investors1 additional known investor

  • University of New Mexico
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China88.9%
🇺🇸 United States11.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HaploX Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HaploX Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.